2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Drug Development, Biological Processes, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

1265 A novel mouse model established by CRISPR/Cas9 with the prothrombin-wauwatosa variant Y287C exhibits the bleeding phenotype in venous injury models

Hongyin Yu, MS, Jeremy P. Wood, PhD2, Jocelyn A Schroeder3, Laura Ketelboeter4, Christian Kastrup5, Shawn M. Jobe6, Qizhen Shi, MD, PhD7
1 Depts of Pediatrics and CBNA, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
2 Dept of Pharmaceutical Sciences, Texas A&M University, Kingsville, Texas, United States
3 Depts of Pediatrics and CBNA, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
4 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
5 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
6 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
7 Depts of Pediatrics and CBNA, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Versiti Blood Research Institute, Milwaukee, Wisconsin, United States

Prothrombin (coagulation factor II, F2), encoded by the F2 gene, is a critical vitamin K-dependent zymogen in the coagulation cascade that is converted to thrombin to drive fibrin clot formation. While the common F2 G20210A variant is associated with elevated prothrombin levels and venous thrombophilia, rare loss-of-function mutations cause congenital prothrombin deficiency, an autosomal recessive bleeding disorder characterized by variable hemorrhagic phenotypes ranging from mild mucocutaneous bleeding to severe life-threatening hemorrhage. Here, we report a novel F2 Y285C (Prothrombin-Wauwatosa) variant, an autosomal dominant variant, which results in a meizothrombin-like product, causing a moderate bleeding phenotype mediated by thrombomodulin-independent protein C activation. To elucidate its functional consequences, we created a CRISPR/Cas9 mouse model (Tosa mice) harboring the orthologous murine variant Y287C. In vivo injury models, including the lateral tail vein transection (TVT) injury model, tail bleeding tests, FeCl3-induced carotid artery injury, and saphenous venipuncture (SVP) injury, and in vitro rotational thromboelastometry (ROTEM) and native whole blood thrombin generation assay (nWB-TGA) were used to assess the functional properties of the Tosa mutation.

Homozygosity at Y287C results in embryonic lethality; thus, heterozygous (Y287C/+) mice were used in our study. Whole blood counts in the Y287C/+ group were similar to wild-type (WT) littermates. The hemostatic parameters determined by ROTEM demonstrated that the clotting time was similar between the two groups, but clot formation time was significantly delayed in the Y287C/+ relative to WT mice (368±117 vs 241±56s, p<0.01), and maximum clot firmness, α-angle, and A10 were significantly lower in the Y287C/+ group. In nWB-TGA, the lag time was significantly prolonged, and peak thrombin, endogenous thrombin potential (EPT), and thrombin generation rate (TGR) in the Y287C/+ group were significantly decreased relative to WT, with TGR most markedly impaired (52.03±9.84 vs 87.03±15.7nM/min, p<0.0001), consistent with our previous observations in plasma from affected patients. In the in vivo TVT test, during the primary bleeding challenge, the bleeding time in the Y287C/+ group was significantly prolonged, and blood loss was more relative to WT (1.36±0.61min and 46.3±53.44µl vs 0.77±0.27min and 7.35±9.25µl, respectively, p<0.01), but no statistically significant differences were noted during the rechallenge bleeding tests. Following SVP injury, bleeding time was significantly prolonged in Y287C/+ mice, but there was no significant difference in the total blood loss between the two groups. In the tail tip injury models, irrespective of cut length (3 mm) or injury size (1.6 mm diameter cut, ~1.5 cm length), there was no difference in bleeding time or blood loss. In the FeCl3-induced carotid artery injury model, occlusion time was comparable between the two groups, but the occlusion reopened in Y287C/+ mice and not in WT animals, suggesting impaired clot stability.

In summary, we have established a novel mouse model with the Y287C/+ variant that recapitulates the bleeding phenotype of patients with prothrombin-Wauwatosa. In vitro, mice with the F2 Y287C/+ variant demonstrate no significant difference in clot formation time but slowed clot formation velocity and decreased clot viscosity and markedly delayed and impaired thrombin generation. Our in vivo results indicate that the F2 Tosa variant differentially impacts hemostatic plug formation in models of venous and arterial injury. Heterozygosity of F2 Y287C primarily impacts the initial hemostatic response to venous injury, while in the FeCl3 model of arterial thrombosis, F2Y87C heterozygosity lessens stable thrombotic occlusion.

Qizhen Shi, MD, PhD: No relevant conflicts of interest to declare.